Assess the long-term efficacy and safety of IpTACopan in patients with C3 glomerulopathy, particularly focusing on those with inflammatory bowel disease (IBD).
Phase 2 extension study design
Comparative analysis of renal outcomes in patients with and without IBD
Multivariate analysis for eGFR slope association
No significant differences in eGFR or proteinuria reduction rates between IBD-associated and non-IBD-associated IgAN
eGFR slope maintained with no association to IBD status
Clinical features and treatment responses were similar across groups
Discussion
No takes yet. Share an insight, caveat, or question.